Toh Y, Yamana H, Shichijo S, Fujita H, Tou U, Sakaguchi M, Kakegawa T, Itoh K
First Department of Surgery, Kurume University School of Medicine.
Jpn J Cancer Res. 1995 Aug;86(8):714-7. doi: 10.1111/j.1349-7006.1995.tb02458.x.
Expression of the MAGE genes encoding tumor-rejection antigens on HLA-A1 and -Cw1601 recognized by cytotoxic T lymphocytes was investigated in esophageal carcinomas at the mRNA level by the semiquantitative reverse transcription-polymerase chain reaction method. MAGE-1 and -2 genes, but not MAGE-3, -3/-6 and -4a/-4b genes, were expressed in substantial proportions of the primary esophageal carcinomas and their metastatic lymph nodes. The proportion of MAGE-positive samples in the primary esophageal carcinomas correlated with the T factor of the TNM classification (pT1: 2 of 12 tumors, pT2: 1 of 6, pT3: 12 of 29, and pT4: 7 of 18). These results have important implications for specific immunotherapy of esophageal carcinomas using MAGE-1 gene product.
采用半定量逆转录-聚合酶链反应方法，在mRNA水平上研究了细胞毒性T淋巴细胞识别的、编码肿瘤排斥抗原的MAGE基因在食管癌中的表达情况。MAGE-1和-2基因在相当比例的原发性食管癌及其转移淋巴结中表达，但MAGE-3、-3/-6和-4a/-4b基因未表达。原发性食管癌中MAGE阳性样本的比例与TNM分类中的T因子相关（pT1：12例肿瘤中有2例，pT2：6例中有1例，pT3：29例中有12例，pT4：18例中有7例）。这些结果对于使用MAGE-1基因产物进行食管癌的特异性免疫治疗具有重要意义。
